The Organisation of Pharmaceutical Producers of India) on Monday said waiving intellectual property rights will not lead to increased production of Covid-19 vaccines, as it is not the barrier to their adequate availability in India. The industry body said it is cognizant that with the rising Covid-19 cases in India and other developing nations, there is an urgency to rapidly-produce greater quantities of Covid-19 vaccine. Vaccine manufacturing is a complex process and scaling up capacities involves the transfer of critical know-how, it added. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has already opposed the transfer of Intellectual Property (IP) waiver saying a waiver is the simple but the wrong answer to what is a complex problem.
